Matinas BioPharma Holdings, Inc.

MTNB
$0.80 (- $0.00 - 0.25%)
Last updated: 2026-06-10 22:25 UTC
MTNB Metrics
Exchange
🇺🇸 NYSE XASE
NYSE Mkt LLCUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS5768103039
CUSIP576810303
Market Price0.8
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-3.42
Market Cap$4.4M
Book Value1.09
Price to Book0.632
Beta1.33
52w High3.09
52w Low0.47
Next Earnings DateN/A

Matinas BioPharma Holdings, Inc. trades under ticker MTNB on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US5768103039, CUSIP 576810303.

About the Company
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Price History